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Abstract
BOYER, BERT B., GERALD V. MOHATT,
ROSEMARIE PLAETKE, JOHANNA HERRON,
KIMBER L. STANHOPE, CHARLES STEPHENSEN,
PETER J. HAVEL, AND THE CANHR PROJECT TEAM.
Metabolic syndrome in Yup’ik Eskimos: the Center for
Alaska Native Health Research (CANHR) Study. Obesity.
2007;15:2535–2540.
Objective: This study investigated the prevalence of meta-
bolic syndrome and its defining components among Yup’ik
Eskimos.
Research Methods and Procedures: A cross-sectional
study design that included 710 adult Yup’ik Eskimos 18
years of age residing in 8 communities in Southwest Alaska.
The prevalence of metabolic syndrome was determined
using the recently updated Adult Treatment Panel III crite-
ria.
Results: The prevalence of metabolic syndrome in this
study cohort was 14.7%, and varied by sex with 8.6% of the
men and 19.8% of the women having metabolic syndrome.
This is lower than the prevalence of 23.9% in the general
U.S. adult population. The most common metabolic syn-
drome components/risk factors were increased waist cir-
cumference and elevated blood glucose. High-density li-
poprotein (HDL) cholesterol levels in Yup’ik Eskimos were
significantly higher, and triglycerides lower than levels re-
ported in National Health and Nutritional Examination III.
Discussion: Compared with other populations, metabolic
syndrome is relatively uncommon in Yup’ik Eskimos. The
higher prevalence among Yup’ik women is primarily ex-
plained by their large waist circumference, suggesting cen-
tral body fat accumulation. Further increases in metabolic
syndrome risk factors among Yup’ik Eskimos could lead to
increases in the prevalence of type 2 diabetes and cardio-
vascular disease, once rare in this population.
Key words: type 2 diabetes, cardiovascular disease,
triglyceride, glucose, insulin
Introduction
The prevalence of obesity, type 2 diabetes (T2D),1 and
cardiovascular disease in Alaskan Eskimos has historically
been low, but recent data indicate a more rapid increase
in these disorders compared with other populations (1,2).
While T2D prevalence among Alaska Eskimos is approxi-
mately one half that of American Indians or all U.S. ethnic
groups combined, the percentage change in T2D preva-
lence in the last 13 years is significantly greater in Alaskan
Eskimos (119%), than for American Indians (82%), or all
U.S. races combined (75%) (personal communication;
Alaska Native Tribal Health Consortium Diabetes Pro-
gram). Available epidemiological data on overweight and
obesity for all Alaska Native groups indicate that increased
obesity prevalence parallels changes in diabetes prevalence
(3). Increased consumption of market foods, reduced phys-
ical activity, stress, depression, smoking, and alcohol con-
sumption have all been thought to contribute to an increased
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prevalence of chronic diseases in Alaskan Eskimo popula-
tions; however, the relative roles of these factors are un-
known.
Metabolic syndrome is characterized by a constellation of
traits that have been shown in combination to be risk factors
for T2D and cardiovascular disease. The most frequently
cited defining criteria for metabolic syndrome are the
World Health Organization (WHO) criteria (4) and the
Adult Treatment Panel III criteria (ATPIII) (5). Recently,
the International Diabetes Foundation (IDF) introduced a
“worldwide” definition for metabolic syndrome (6). All
criteria include abdominal obesity, an index of insulin re-
sistance/glucose intolerance, dyslipidemia, and hypertension.
We sought to determine the prevalence of metabolic
syndrome and its component risk factors in Yup’ik Eski-
mos. We used the updated ATPIII criteria (7) for three
reasons: First, the WHO criteria require administration of an
oral glucose tolerance test, and these data are not available
for our study population. Second, the IDF criteria intro-
duced ethnic-specific thresholds for waist circumference
that are not defined for Alaska Natives. Third, the American
Heart Association and the NIH continue to support the use
of the ATPIII criteria recently published in a joint scientific
statement (8).
An estimated 47 million people in the United States meet
the criteria for metabolic syndrome (9), and the prevalence
widely varies among different ethnic groups within the
United States (10) and throughout the world (11). Evalua-
tions of change in the individual components defining met-
abolic syndrome indicate that the prevalence is increasing
(10). The prevalence of metabolic syndrome has not been
reported in Alaskan Eskimos in general, or Yup’ik Eskimos,
in particular. A recent report evaluated the prevalence of
metabolic syndrome in Greenlandic Inuit, who are ethni-
cally and culturally similar to Alaskan Yup’ik Eskimos
(also Inuit), and determined the ATPIII and WHO preva-
lence to be 17.9% and 20.7%, respectively (12).
The primary aim of the Center for Alaska Native Health
Research (CANHR) study is to identify behavioral, genetic,
and nutritional risk factors contributing to obesity and T2D
in Yup’ik Eskimos residing in Southwest Alaska (13). Be-
cause metabolic syndrome increases an individual’s risk for
T2D, we also sought to determine the prevalence of meta-
bolic syndrome in Yup’ik Eskimos as a secondary analysis.
Research Methods and Procedures
Recruitment of study participants started in December
2003 and continued through March 2006. All residents from
8 communities were invited to participate. Communities
were stratified by size and key cultural factors representa-
tive of the diversity of the region. The age distribution of the
study population reflects the age distribution among eligible
participants based on the U.S. 2000 census (Kolmogorov
Smirnov test, p  0.05). All participants were consented
using protocols approved by the University of Alaska Insti-
tutional Review Board, the National and Area Indian Health
Service Institutional Review Boards, and the Yukon Kus-
kokwim Human Studies Committee.
We enrolled a total of 907 participants and 872 partici-
pants completed the study. The analysis for this report is
based on participants who identified themselves as non-
pregnant Alaska Natives, 18 years old, and having fasted
at least 8 hours. Data for all 5 metabolic syndrome compo-
nents were available for 710 adult Yup’ik Eskimos. Anthro-
pometric measurements were obtained by trained observers
using previously published protocols implemented in the
National Health and Nutritional Examination (NHANES)
III survey (14). Leptin was assayed with a radioimmuno-
assay kit using an I125-iodinated human leptin tracer and
human leptin standards from Linco Research, Inc.
(St. Charles, MO), and the intra- and inter-assay variations
were 6.6% and 12.0%, respectively. Adiponectin was as-
sayed with a radioimmunoassay kit using a I125-iodinated
murine adiponectin tracer, a multi-species adiponectin rab-
bit antiserum, and human adiponectin standards from Linco
Research. The adiponectin intra- and inter-assay variations
were 5.1% and 9.1%, respectively. Insulin was assayed
with a radioimmunoassay kit using a I125-iodinated insulin
tracer, anti-human insulin-specific antibody, and human in-
sulin standards from Linco Research, and the intra- and
inter-assay variations were 5.8% and 10.2%, respectively.
C-reactive protein (CRP) was measured with an Immulite
Analyzer and high sensitivity CRP reagents from Diagnos-
tic Products Corporation (Los Angeles, CA). Manufactur-
er’s intra- and inter-assay variations were 2.8% and 3.3%,
respectively. Low-density lipoprotein cholesterol, high-
density lipoprotein (HDL) cholesterol, and triglycerides
were measured with the Poly-Chem System Chemistry
Analyzer (Polymedco Inc., Courtlandt Manor, NY) in the
Nutritional Assessment Laboratory, School of Medicine,
University of California at Davis. Laboratory intra- and
inter-assay variations were 3.6% and 3.9%, respectively, for
HDL-cholesterol; 1.8% and 6.2%, respectively, for choles-
terol; and 3.2% and 4.1%, respectively, for triglycerides.
Fasting blood glucose was measured on a Cholestech
LDX analyzer and glycosylated hemoglobin was measured
on a Bayer HbA1c DCA 2000 analyzer (Bayer AG,
Leverkusen, Germany).
Waist circumference was measured with a Gulick II
150-cm tape measure (Country Technologies, Inc., Gays
Mills, WI) immediately below the lowest lateral portion of
the rib case, and percentage body fat was estimated by
electrical bioimpedance using a Tanita TBF-300A body fat
analyzer (Tanita Corp., Arlington Heights, IL). We classi-
fied individuals with the metabolic syndrome according to
the new ATPIII criteria (7). We also calculated prevalence
in our Yup’ik Eskimo participants using IDF South Asian/
Chinese waist circumference cut-off recommendations
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(90 cm for males and 80 cm for females) and Europid
cut-off criteria (94 cm for males and80 cm for females)
(6). Cardiovascular disease risk was estimated according to
the Framingham criteria including low-density lipoprotein
cholesterol (15).
Statistical Analysis
Descriptive statistical analysis was performed to deter-
mine frequency distribution of variables, location (mean),
and dispersion parameters (standard deviation, standard er-
ror, and range). The non-parametric Mann-Whitney test was
applied to test differences between men and women within
the CANHR sample (16). The direct method was applied to
adjust for age and sex for estimating the prevalence of the
metabolic syndrome (17). Univariate ANOVA was per-
formed to correct for age, sex, and BMI in the analyses of
the components of metabolic syndrome. All statistical tests
were two-sided with a significance level of p 0.05. Partial
correlation coefficients were estimated for the components
defining metabolic syndrome and after correcting for BMI,
age, and sex. Before including these covariates in the anal-
ysis, their significant effects were evaluated with univariate
ANOVA. Statistical analyses were performed with SPSS
version 14.0 (SPSS, Inc., Chicago, IL). We extracted and
analyzed data from the NHANES III (1988 to 1994). The
data were processed and distributed with permission from
the Population Research Institute, Simple On-line Data Ar-
chive for Population Studies (16). All NHANES biochem-
ical measures, except for fasting glucose, were taken from
serum instead of plasma. BMI was calculated as recom-
mended by the NHANES III Public-Use Data Files Errata.
Identical inclusion/exclusion criteria were applied to the
NHANES and CANHR sample.
Results
A comparison between our study population and
NHANES sample regarding age, anthropometric, and met-
abolic characteristics is presented in Table 1. Participants’
age ranged between 18 and 94 years, and their age distri-
bution was not different from that of the general population
residing in participating villages. Fifty-three point nine per-
cent of the participants were female, and the ages of men
and women participating in the study were not significantly
different regarding age (Mann-Whitney, p  0.580).
On average, women were shorter, significantly more
overweight (as estimated by BMI and percentage body fat),
and had greater waist circumference than men. Men had
higher systolic and mean arterial pressure than women.
Total cholesterol, low-density lipoprotein cholesterol, and
triglyceride levels were not significantly different between
men and women; however, women did have higher HDL
cholesterol levels than men. Women also had significantly
higher plasma leptin and insulin concentrations than men.
Glucose, high sensitivity CRP, and adiponectin concentra-
tions were not significantly different between men and
women.
The age-adjusted prevalence of metabolic syndrome in
Yup’ik Eskimos was 16.9%, and the prevalence for women
was 20.7%, compared with 9.6% for men. In compari-
son, using the South Asian/Chinese IDF criteria, the age-
adjusted prevalence of metabolic syndrome, increased to
22.3% for women and 10.8% for men. Finally, using the
Europid waist circumference cut-off, the prevalence of met-
abolic syndrome was 22.3% for women and 8.6% for men.
In the remainder of the study, we only present results based
on the most recent ATPIII criteria.
The presence of additional metabolic parameters associ-
ated with obesity, T2D, atherosclerotic cardiovascular dis-
ease, and metabolic syndrome were also evaluated. These
endophenotypes included leptin as a marker for obesity, and
CRP and adiponectin as measures of the pro-inflammatory
status and cardiovascular disease risk (18). Fasting plasma
insulin concentrations and homeostasis model assessment of
insulin resistance values were studied to evaluate the degree
of insulin resistance. The results from this analysis are
presented as a function of the number of metabolic syn-
drome components present (Table 2). These 4 groups are
significantly different regarding sex, age, and BMI
(ANOVA, all p  0.05); therefore, Table 2 presents mean
values adjusted for these covariates. The average age for the
participants without any metabolic syndrome risk factors
was 34 years (range, 18 to 75 years), compared with 40
years (range, 18 to 94 years) for individuals with 1 risk
factor, 46 years (range, 18 to 82 years) for participants with
2 risk factors, and 52 years (range, 18 to 91 years) for those
with metabolic syndrome. There was a clear trend for
plasma adiponectin levels to decrease with increasing num-
bers of abnormal metabolic syndrome components; plasma
leptin, insulin, homeostasis model assessment of insulin
resistance values, and Framingham Risk scores increased
with increasing numbers of risk factors. However, not all
pairwise comparisons were significant (Table 2). No clear
trend could be observed between groups for plasma CRP
concentrations.
Discussion
The prevalence of metabolic syndrome among Yup’ik
Eskimos (14.7%) is lower than that observed in NHANES
III (23.9%), Greenlandic Eskimos (17%) (12), and several
other Native American and non-Native groups (10,11). The
mean age of the participants with metabolic syndrome was
52 years and is similar to NHANES III (57 years) and
Greenlandic Inuit (54 years) with metabolic syndrome (12).
A large waist circumference is the most common risk factor
for metabolic syndrome in Yup’ik Eskimos and was more
common in women than men (59.3% of women vs. 15.9%
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of men). Higher HDL cholesterol and normal plasma tri-
glyceride concentrations contribute to the overall low prev-
alence of metabolic syndrome in this population. This fa-
vorable lipid profile may be explained, in part, by a diet rich
in salmon and marine mammals that are high in polyunsat-
urated fatty acids (19).
Additional endophenotypes associated with obesity,
insulin resistance, and cardiovascular disease included
plasma leptin concentrations, which were increased, whereas
plasma adiponectin levels were decreased with increasing
numbers of metabolic syndrome components. CRP levels were
not significantly elevated with increasing components for
Table 1. Anthropometric and biochemical measures by gender
NHANES III
CANHR
p
Total
CANHR Females Males
Sex (n) 10,843 710 383 327
Age (yr) (mean  SD) 47 21 41  16 41  16 40  16 0.58
Height (cm)* (mean  SD) 166.4 10.0 160.8 8.7 155.7  6.3 166.9  7.2 0.001
Weight (kg) (mean  SD) 74.7 18.0 72.3  15.2 71.9  16.8 72.7  13.1 0.122
BMI (kg/m²)* (mean  SD) 27.0 5.8 28.0  6.0 29.7  6.9 26.0  4.1 0.001
Percentage body fat* (mean  SD) Not available 29.6 10.8 36.3  8.8 21.7  7.1 0.001
Waist circumference (cm)† (mean  SD) 92.4 14.5 91.4  14.3 92.8  15.9 89.9  12.1 0.021
n (%) with abnormal value‡ 278 (39.2) 226 (59.0) 52 (15.9)
Blood pressure
Mean arterial pressure* (mean  SD) 89.0 13.0 88.0  10.3 86.9  11.3 89.3  9.4 0.001
Systolic BP* (mean  SD) 122.7 20.7 121.5 14.8 119.0 15.8 124.4 12.9 0.001
n (%) with abnormal value§ 161 (22.7) 75 (19.6) 86 (26.3)
Diastolic BP (mean  SD) 72.2 12.6 71.2 10.3 70.9  10.8 71.7  9.6 0.102
n (%) with abnormal value 69 (9.7) 41 (10.7) 28 (8.6)
Biochemical measures
Cholesterol (mg/dL) (mean  SD) 203.3 44.0 220.0 46.2 220.9 45.0 219.0 47.7 0.497
HDL (mg/dL)* (mean  SD) 50.9 15.1 61.9  17.8 65.1  18.3 58.1  16.5 0.001
n (%) with abnormal value 90 (12.7) 69 (18.0) 21 (6.4)
LDL (mg/dL) (mean  SD) 127.0 38.5 141.3 38.5 139.2 36.9 143.7 40.3 0.224
Triglyceride (mg/dL) (mean  SD) 135.1 105.8 84.4 48.4 82.7  40.1 86.4  56.7 0.866
n (%) with abnormal value** 48 (6.8) 25 (6.5) 23 (7.0)
Fasting glucose (mg/dL) (mean  SD) 101.5 31.6 94.2 13.3 94.0  15.1 94.5  10.8 0.065
n (%) with abnormal value†† 170 (23.9) 85 (22.2) 85 (26.0)
Insulin (U/mL)* (mean  SD) 11.1 8.0 14.7 8.3 15.9  9.2 13.2  6.8 0.001
Adiponectin (g/mL) (mean  SD) Not available 10.1 5.5 10.3  6.0 9.7  5.0 0.37
Leptin (ng/mL)* (mean  SD) Not available 11.0 10.2 17.1 10.1 3.8  3.5 0.001
C-reactive protein (mg/dL) (mean  SD) 0.48 0.80 0.36  1.01 0.27  0.57 0.49  1.40 0.11
CANHR, Center for Alaska Native Health Research; NHANES, National Health and Nutritional Examination; SD, standard deviation; BP,
blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
* Mann-Whitney p  0.001 by gender within CANHR population.
† Mann-Whitney p  0.05 by gender within CANHR population.
‡ Women, waist circumference 88 cm; men, waist circumference 102 cm.
§ Women and men: systolic blood pressure 130 mm Hg; women and men: diastolic blood pressure 85 mm Hg.
 Women: HDL 50mg/dL, Men: HDL 40 mg/dL.
** Women and men: triglyceride 150 mg/dL.
†† Women and men: fasting glucose 100 mg/dL.
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metabolic syndrome; nevertheless, the Framingham risk score
did increase in parallel with an increasing number of meta-
bolic syndrome defining components further suggesting an
increased risk for cardiovascular disease.
Despite a high prevalence of increased central adiposity,
particularly in women, Yup’ik Eskimos seem to be some-
what protected from metabolic syndrome. Like their Green-
landic Inuit Eskimo counterparts, Yup’ik Eskimos have
lower triglycerides, lower fasting glucose, and higher HDL
cholesterol levels (20) compared with northern Europeans.
A traditional diet rich in polyunsaturated fatty acids may
play a role in protecting Yup’ik Eskimos from dyslipidemia
and hyperglycemia associated with metabolic syndrome,
while at the same time reducing pro-inflammatory cytokines
and increasing adiponectin levels. Maintaining a traditional
Yup’ik diet and encouraging an active lifestyle may ulti-
mately serve to curb potential increases in the prevalence of
metabolic syndrome and also prevent the onset of T2D
atherosclerotic cardiovascular disease in Yup’ik Eskimos
and other Inuit groups.
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